健民集团：鼻渊通窍颗粒药物临床试验获批准

Core Viewpoint - The company, Jianmin Group, has received approval from the National Medical Products Administration for clinical trials of its nasal medication, indicating a significant step in the development of a treatment for acute sinusitis [1] Company Summary - Jianmin Group (stock code: 600976) announced on August 14 that it has obtained the "Drug Clinical Trial Approval Notice" for its product, Nasal Congestion Relief Granules [1] - The approved indication for this medication is acute sinusitis, which suggests potential market opportunities in addressing this common health issue [1]